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INTRODUCTION
Multiple endocrine neoplasia type 2A (MEN 2A) is a syndrome of familial neoplasias, transmitted in an autosomal dominant fashion and characterized by medullary thyroid carcinoma (MTC), pheochromocytoma and hyperplasia of the parathyroid glands. In MEN 2A about 90% of adult carriers of the mutated gene will develop MTC, 50% unilateral or bilateral pheochromocytoma and 20-30% parathyroid tumors. 1 RET protooncogene mutations have been identified as the responsible molecular defect for MEN 2A. [2] [3] [4] The RET gene is located on 10q11.2, comprises 21 exons and encodes a single-pass transmembrane receptor tyrosine kinase. [5] [6] [7] Most MEN 2A mutations affect cysteines in the cysteine-rich extracellular portion of RET and result in constitutive activation of tyrosine kinase through the formation of disulfide-bonded RET homodimers (Table 1) . In more than 96% of MEN 2A families, single base pair mutations in exon 10 (codons 609, 611, 618, 620) or exon 11 (codon 634) have been identified. 2, 3, [8] [9] [10] We herein report a patient with MEN 2A harboring a mutation (Gly 533 Cys) in exon 8. This missense point mutation has recently been associated with familial MTC (FMTC), 11, 12 but mutations in exon 8 have not previously been identified in MEN 2A patients. Interestingly, our patient was presented with bilateral pheochromocytomas, whereas MTC was not clinically apparent.
SUbJECTS AND METHODS

Patient's description
A 66-year old Greek male patient was referred to the Endocrinology Department of the Athens Polyclinic for further assessment of bilateral adrenal nodules. The patient had a ten-year history of persistent hypertension under treatment with amilodipine without episodes of headache, sweating attacks or tachycardia. An ultrasound scan of the abdomen showed a right adrenal mass; subsequently, an adrenal computed tomography revealed bilateral adrenal nodules (right: maximum diameter 3.5 cm; left: maximum diameter 2.5 cm).
The patient's family history was remarkable for the presence of pheochromocytoma in his mother and persistent hypertension in his mother's two sisters and one brother (Figure 1 14, 15 To the best of our knowledge, no molecular abnormalities of RET exon 8 have previously been reported in patients with MEN 2A syndrome. Therefore, this is the first report of a case of MEN 2A associated with the new RET mutation in exon 8, codon 533 caused by a substitution of a glycine by a cysteine in the cysteine-rich extracellular portion of RET receptor. MEN 2A carrier determination is one of the few examples of a genetic test that mandates a highly effective clinical intervention. 16 Several significant observations emerge from the characterization of our patient with this novel RET mutation causing MEN 2A syndrome. First, while no clinical or biochemical evidence of pheochromocytoma was observed in the 76 patients with the Gly 533 Cys substitution in RET exon 8 studied by Αlvares Da Silva et al, 11 bilateral pheochromocytoma was the presenting feature in our patient; secondly, a least aggressive form of MTC is documented by the fact that our patient had no evidence of clinically apparent MTC at the age of 66 yr and no other family members died from performed and histological examination showed the presence of MTC. Genetic testing for the presence of a RET mutation was then recommended.
DNA analysis and mutation detection
Genomic DNA was prepared from peripheral blood samples collected on EDTA tubes according to standard protocols. The sequences of primers for exons 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21 were used and PCR protocols were obtained from previously published sources. 11, 13 Sequencing was performed in a genetic analyzer ABI3100.
RESULTS
The patient's genomic DNA was initially screened for RET mutations in exons 10, 11, 13, 14, 15 and 16. As no molecular abnormalities were observed, analysis was extended to exons 7, 8, 9, 12, 17, 18, 19 and 21 of the RET gene in accordance with the guidelines for the diagnosis and therapy of MEN type 2 syndromes. 1 Direct sequencing of exon 8 PCR products from genomic DNA revealed a G to T transversion in the heterozygote state at position 1597, which leads to a Gly to Cys amino-acid change at codon 533 (Figure 4) . Since the above nucleotide change has been reported previously as the cause of FMTC in three large families, 11, 12 it was assumed that it is the cause of the disease in this patient too.
DISCUSSION
So far, mutations at RET exon 8 have been identified in patients with FMTC only. Pigny et al demonstrated the presence of a germline 9-bp duplication in RET exon 8 in all MTC patients of a large family with FMTC. The above duplication created an additional cysteine codon in the extracellular cysteine-rich domain of RET. 13 Αlvares Da Silva et al described a missence point mutation in exon 8 of the RET gene (1597G→T) that corresponded to a Gly 533 Cys substitution in 76 patients from a 6-generation Brazilian family with 229 subjects. 11 Furthermore, Kaldrymides et al reported similar findings in two Greek families. 12 Interestingly, none of the affected patients in these two studies with the Gly 533 Cys missense mutations showed evidence of pheochromocytoma. We report causes related to MTC. It is interesting to note that all mutations that have previously been associated with pheochromocytoma demonstrated an earlier onset of MTC. 17 It is understood that, due to the small number of patients with exon 8 mutations and the variable expression, it is not possible to calculate the penetrance of these mutations. Hence, follow-up of these cases is needed to ascertain the presence of tumors encountered in MEN 2A syndrome and their age-related progression. Moreover, as already pointed out by Moers et al, 18 our case illustrates the difficulty in the distinction between FMTC and MEN 2 syndrome.
In conclusion, in patients with clinical suspicion of MEN 2A syndrome the analysis of RET exon 8 should be considered when routine evaluation of MEN 2A-associated mutations is negative. Moreover, the case illustrates that, despite the absence of pheochromocytoma in individuals with exon 8 mutations thus far reported, pheochromocytoma should be considered in patients with this rare mutation.
